Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

Atherosclerotic plaques are not only lipid deposits; they also contain inflammatory and senescent cell populations that can destabilize the vascular environment. The 2025 study by Zheng and colleagues examines how berberine limits this inflammatory aging phenotype through an RXRα/PPARγ/NEDD4 signaling axis. The full reference is available through the published study in the American Journal of Chinese Medicine.

Study Background and Research Question

Senescent cells remain metabolically active and release cytokines, chemokines, growth factors, and matrix-remodeling factors collectively known as the senescence-associated secretory phenotype, or SASP. In the arterial wall, this secretory program can sustain local inflammation and influence plaque composition. Human carotid plaque single-cell sequencing has identified abundant senescent foam-cell populations, supporting the view that macrophage-derived foam cells are important contributors to vascular inflammatory aging.

The study focused on a central unresolved question: how does berberine, a bioactive compound with reported anti-senescence effects, suppress SASP-related inflammation in atherosclerosis? Rather than treating the response as a nonspecific reduction in inflammatory markers, the investigators sought to connect berberine exposure to receptor signaling, transcriptional regulation, and protein turnover. This approach is important because a decrease in SASP proteins alone does not establish whether a treatment changes the senescence program directly or simply dampens downstream inflammation.

The authors proposed that RXRα and PPARγ form a functionally relevant receptor complex in macrophage-derived foam cells. They then investigated whether this complex regulates NEDD4, an ubiquitin-related regulatory enzyme, and whether NEDD4 controls inflammatory protein production through the GATA4/p62 complex.

Key Innovation from the Reference Study

The main innovation is the proposed mechanistic chain linking nuclear-receptor activity to ubiquitination-mediated suppression of SASP. According to the reference study, berberine activates RXRα and PPARγ in foam cells, increases NEDD4 transcriptional activity, and promotes ubiquitination and degradation of the GATA4/p62 complex. This provides a molecular explanation for how receptor-level signaling can alter the stability of proteins associated with inflammatory aging.

This model extends the conventional view of PPARγ biology. PPARγ is widely studied in lipid metabolism, macrophage function, and adipocyte differentiation, but the study positions PPARγ within a broader PPARγ/RXRα heterodimer modulation mechanism that is connected to protein quality control. The proposed pathway is therefore not limited to transcriptional activation of metabolic genes. It also involves regulation of a protein complex whose turnover influences SASP-associated inflammatory output.

A second innovation is the use of macrophage-specific RXRα knockdown as a functional test. If berberine merely acted through an unrelated antioxidant or anti-inflammatory route, reducing RXRα in plaque macrophages might have had little effect on treatment response. Instead, the loss of berberine’s anti-aging impact after RXRα knockdown supports the importance of RXRα-dependent signaling in the observed phenotype.

Methods and Experimental Design Insights

The investigators combined an in vivo atherosclerosis model with complementary cellular systems. ApoE-deficient mice fed a high-fat diet were used to evaluate plaque morphology, blood chemistry, and the response to berberine treatment. In parallel, RAW264.7 macrophages and primary peritoneal macrophage-derived foam cells were examined for SASP-related proteins and pathway activity. This combination allowed the authors to ask whether molecular findings in cultured foam cells were consistent with changes in plaque-associated inflammation.

Smart-seq analysis was used to explore transcriptional pathways associated with berberine treatment. The transcriptomic data directed attention toward RXRα, PPARγ, and NEDD4, after which the investigators used biochemical and cellular analyses to examine receptor activation, GATA4/p62 interactions, ubiquitination, and inflammatory protein production. This sequential design is stronger than relying on transcriptomics alone because it connects gene-expression changes with protein-level mechanisms.

The causal component involved lentivirus-mediated RXRα knockdown in macrophages within plaques, using the CD68 promoter strategy described in the study. This intervention tested whether macrophage RXRα was required for berberine-mediated improvement in the atherosclerotic phenotype. The design also highlights an important principle for pathway research: receptor expression or activation should be perturbed in the disease-relevant cell population rather than only in a generic cell line.

Protocol Parameters

• In vivo disease model: use ApoE-deficient mice on a high-fat diet to model plaque development; the reference study evaluated plaque morphology and blood chemistry before and after berberine treatment.
• Cellular systems: compare RAW264.7 macrophages with primary peritoneal macrophage-derived foam cells to distinguish findings that are conserved across a cell line and a primary-cell model.
• Pathway readouts: measure SASP-associated inflammatory proteins together with RXRα/PPARγ activity, NEDD4 expression, GATA4/p62 association, and ubiquitination status.
• Transcriptomic discovery: use Smart-seq or a comparable expression-profiling workflow to identify treatment-responsive pathways, then validate candidate targets at the protein and functional levels.
• Causal perturbation: apply macrophage-focused RXRα knockdown when testing pathway dependence. These parameters summarize the published design; specific berberine doses, treatment intervals, and assay settings should be taken from the full experimental methods rather than inferred from the abstract.

Core Findings and Why They Matter

Berberine reduced SASP-related inflammation in the atherosclerosis model and in macrophage-derived foam-cell systems. The cellular experiments indicated that treatment increased GATA4 binding to p62, promoted ubiquitination of the GATA4/p62 complex, and reduced production of SASP-associated proteins. The findings place GATA4/p62 turnover downstream of receptor signaling rather than treating it as an isolated inflammatory marker.

At the transcriptional level, berberine activated RXRα and PPARγ and increased NEDD4 transcriptional activity. NEDD4 appears to function as the link between receptor signaling and ubiquitination-dependent degradation of the GATA4/p62 complex. The resulting decrease in SASP-related protein production offers a mechanistic explanation for reduced inflammatory activity in foam cells.

The in vivo knockdown experiment was particularly informative. Macrophage-specific depletion of RXRα weakened or abolished berberine’s anti-aging effect in ApoE-deficient mice, indicating that RXRα is not merely correlated with treatment response. The result supports a model in which RXRα is required for effective PPARγ-associated signaling in plaque macrophages.

These observations matter for three reasons. First, they connect vascular senescence with a defined nuclear-receptor and ubiquitination pathway. Second, they suggest that controlling the SASP may involve regulating protein degradation, not only blocking cytokine receptors. Third, they provide a testable framework for separating receptor-dependent effects of berberine from its other biochemical activities. The study does not establish that all effects of berberine in atherosclerosis are mediated by this pathway, but it identifies a coherent and experimentally tractable mechanism.

Comparison with Existing Internal Articles

The internal article Berberine Suppresses SASP in Atherosclerosis via RXRα/PPARγ/NEDD4 provides a concise overview of the same pathway and emphasizes its relevance to macrophage-driven vascular aging. The present analysis complements that resource by focusing on the logic of the experimental design: transcriptomic discovery was followed by molecular validation and then by macrophage-specific RXRα knockdown. That progression is useful when planning experiments intended to distinguish pathway association from functional dependence.

Limitations and Transferability

The study has several limitations that should shape interpretation. The primary disease evidence comes from a mouse model, and ApoE deficiency with a high-fat diet does not reproduce every feature of human plaque biology. Although the work is motivated by human carotid single-cell observations, the intervention itself does not constitute evidence of clinical efficacy in patients. Translation will require confirmation in human plaque material, human macrophage or foam-cell systems, and models that better capture plaque instability and treatment exposure.

Smart-seq can reveal treatment-associated transcriptional programs, but expression changes do not by themselves prove direct receptor binding or direct transcriptional control. The knockdown experiment strengthens the case for RXRα dependence, yet RXRα reduction may alter several downstream pathways simultaneously. Likewise, the reported activation of PPARγ does not establish whether berberine directly binds PPARγ, changes receptor cofactor recruitment, or acts through RXRα-dependent receptor cooperation.

Additional controls would be valuable in future studies. These could include independent RXRα perturbation strategies, rescue experiments, direct chromatin or promoter assays for NEDD4 regulation, and separation of GATA4/p62 degradation from general changes in proteostasis. It will also be important to determine whether the pathway operates similarly in different plaque macrophage states and whether reducing SASP improves plaque stability independently of changes in lipid burden.

For researchers, the key transferable lesson is methodological rather than therapeutic: combine disease-relevant cell targeting with transcriptomic discovery, protein-level validation, and a loss-of-function test. A PPARγ signaling pathway inhibitor or other selective receptor perturbation can be useful in this framework, but pharmacological inhibition should be interpreted alongside genetic controls because receptor antagonism may affect adipocyte, macrophage, or cell-cycle programs beyond the specific pathway under study.

Research Support Resources

Researchers can use T0070907 (SKU A4301) as a selective PPARγ antagonist to support related receptor-dependence experiments. The product information reports an IC50 and Ki of 1 nM and covalent interaction with cysteine 313 of human PPARγ2; these values should be interpreted as product characterization rather than measurements from the berberine study. In a follow-up design, T0070907 could help test whether berberine responses require PPARγ activity, while RXRα knockdown would address the complementary receptor component.

Why this cross-domain matters, maturity, and limitations

T0070907 is also used in separate contexts involving adipogenesis inhibition and cell cycle G2/M arrest. Those applications may help researchers benchmark PPARγ perturbation in other cellular assays, but they are not outcomes demonstrated by the reference paper and should not be presented as evidence for efficacy in atherosclerosis. Because antagonism does not reproduce berberine-mediated RXRα activation or NEDD4 induction, appropriate vehicle controls, genetic validation, and pathway-specific readouts remain essential.